CTMX Profile
CytomX Therapeutics Inc. (CTMX) is a clinical-stage, oncology-focused biopharmaceutical company that develops novel cancer immunotherapies based on its Probody technology platform. The Probody platform enables the company to design and develop therapies that selectively target cancer cells while sparing healthy tissues. The company's lead candidate, CX-072, is a Probody therapeutic that targets the PD-L1 protein, which is overexpressed in multiple tumor types, and is being developed in partnership with Bristol-Myers Squibb. The company also has a broad pipeline of Probody therapeutics targeting various oncology targets, including CX-2009, a Probody drug conjugate (PDC) targeting the CD166 antigen, which is being developed for the treatment of cancer.
In addition to its Probody platform, CytomX has developed the ProCAR-NK platform, a CAR-NK cell therapy platform that enhances the natural killer (NK) cell's ability to recognize and destroy cancer cells. The company is also exploring the use of its Probody platform in other therapeutic areas, including inflammation and autoimmune diseases.
CytomX is headquartered in South San Francisco, California, and was founded in 2008. The company went public in 2015 and trades on the NASDAQ under the ticker symbol CTMX.
|
